Letrozole Hilma Biocare

Letrozole by Hilma Biocare, sold medically as Femara, is one of the most powerful aromatase inhibitors available for controlling estrogen. Originally developed to treat hormone-receptor-positive breast cancer, it has become a key ancillary for athletes running aromatizing steroids, prized for its ability to strongly suppress estrogen and even reverse existing gynecomastia. Because it is so potent, it is used carefully and at low doses to keep hormonal balance without crashing estrogen entirely.
| Active substance | Letrozole |
| Manufacturer | Hilma Biocare |
| Form | Oral tablets |
| Typical dosage | 0.25–0.5 mg every other day |
| Class | Non-steroidal aromatase inhibitor |
| Primary use | Strong estrogen control, gyno reversal |
Effects and benefits
Letrozole can lower estrogen by up to the high nineties in percentage terms, which is why it is reserved for heavy aromatizing cycles or for reversing gyno that milder inhibitors cannot handle. Controlling estrogen this way also helps limit water retention and supports higher free testosterone.
- Powerfully reduces estrogen levels
- Can reverse existing gynecomastia
- Cuts water retention and bloat
- Supports higher free testosterone
Dosage and administration
Because of its strength, most users run just 0.25–0.5 mg every other day and titrate to bloodwork and symptoms, avoiding an estrogen crash. As an ancillary it belongs in a structured post cycle therapy and on-cycle support plan rather than in the anabolic stack itself.
Stacking and combinations
For lighter cycles many prefer the gentler control of Anastrozole or Exemestane, keeping Letrozole in reserve for heavy aromatization or active gyno.
Why choose Hilma Biocare
Every batch is produced to consistent pharmaceutical standards with dependable dosing you can trust with such a strong compound. Explore the complete Hilma Biocare catalogue to assemble a matching support protocol.
| Characteristics | |
| Shelf Life | 36 months from manufacture date |
| Drug Class | Aromatase Inhibitor |
| Concentration | Typically 2.5 mg per tablet |
| Half-Life | Approximately 2-4 days |
| Detection Time | Not typically tested in standard drug screenings |
| Active Substance | Letrozole |
| Dosage | 0.5-1 mg every 1-3 days |
| Drug Category | Post Cycle Therapy |
| Form | Oral tablets |
| Product Packaging | 30 tablets |
| Progestational Activity | None |
| Liver Toxicity | Low |
| Chemical Structure | C17H11N5 |
| Estrogenic Activity | Antagonist |
